At Novartis, we use science-based innovation to address some of society’s most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible. As a global company, we have a great responsibility and an even greater opportunity to lead the world in creating a positive social change, embracing societal impact as a core business objective.

Silvia Bally, a Novartis employee at a production facility in Stein, Switzerland

Novartis in Society Integrated Report 2021

The Novartis in Society Integrated Report highlights progress against our strategy and describes how we create value for our stakeholders. This report combines our Novartis in Society ESG Report and Annual Review.

Learn More

Novartis ESG Investor Day 2021

At its eighth annual ESG investor event, Novartis shared progress against its Environmental, Social and Governance (ESG) targets and updated on its most material ESG topics, including access to medicines, patient health and safety, innovation and ethical standards.

Read the Media Release

760+m

Patients reached

155

Countries where Novartis products are sold

-7.7bn

Environmental impact (USD) of our activities for 2020

242bn

Social impact (USD) of our products for 2020*


Building Trust with Society

Building trust with society is a key pillar of the Novartis corporate strategy and is critical to delivering on our purpose of reimagining medicine to improve and extend people’s lives. It defines our approach to managing our key environmental, social and governance (ESG) topics and risks: being part of the solution on pricing and access, addressing global health challenges, being a responsible citizen, and holding ourselves to high ethical standards. Our ESG efforts are fully integrated across the company and are key to driving long-term value for our stakeholders.

We believe a focus on our material ESG topics, coupled with our inspired, curious and unbossed culture will drive better performance.  ESG topics form a core component of how the Novartis Executive Committee and the Board of Directors evaluate long-term performance of the company. We are committed to reporting transparently on these topics through our Annual Reporting Suite, which includes the Novartis in Society Integrated Report, as well as our other Publications.

We aim to conduct business responsibly wherever we operate with a focus on building a strong ethical foundation, respect for human rights, patient health and safety, diversity and inclusion and the safety and well-being of our employees. We have clear commitments on many other social topics including the living wage, product quality and use of animals in research.


Thierry Diagana, Head of the Novartis Institute for Tropical Diseases (NITD)

Staying one step ahead of the malaria parasite

Thierry Diagana and his team are on a quest to discover new therapeutics for malaria. He believes malaria elimination is within our grasp, but emerging drug resistance could jeopardize the hard-fought progress.

Lutz Hegemann, M.D., Ph.D.

Doing the right thing is good business

Lutz Hegemann shares how lessons learned treating patients with leprosy influenced the way he thinks about the pharmaceutical business.

Read More
Business people discussing outdoor

Integrating ESG into strategy – Novartis Lecture 2021

Not a nice-to-have asset, but rather a critical driver for business and impact: watch the recording of the 2021 Novartis Lecture by Prof. George Serafeim from Harvard Business School on how to successfully integrate ESG objectives into corporate strategy.

Watch

Materiality Assessment and Impact Valuation

Our ESG priorities are defined by our materiality assessment, it helps us understand what matters to our stakeholders and how they perceive our impact.

Learn More about our materiality assessment

Corporate Governance

Our corporate governance framework supports sustainable financial performance and long-term value creation and is aligned with our values and behaviors. In a rapidly changing business environment, we apply effective risk management to build resilience. We continue taking important steps to integrate our ESG agenda into the core of our business, enhancing executive accountability and measuring our performance against transparent targets. Members of the Executive Committee and other senior leaders have ESG targets in their annual objectives.


People relaxing in the Novartis Basel campus

Environmental, Social and Governance (ESG) Index

Novartis aims to report comprehensively and transparently about ESG topics. We have created a set of environmental, social and governance indices to signpost where our key disclosures can be found across our publications and channels.

Learn More

* Based on 68 Innovative Medicines brands and 71 Sandoz products in 131 countries